15 January 2023 - Akeso announced that the anti PD-1 monoclonal antibody drug penpulimab, co-developed by the Company with Sino Biopharmaceutical, combined with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer has been granted marketing approval by the National Medical Products Administration of China.

The approval of new indication is based on a randomised, double-blind, multi-centre Phase 3 clinical trial (AK105-302), with 350 locally advanced or metastatic patients with squamous non-small cell lung cancer who have not received prior systemic therapy.

Read Akeso press release